AZN

AstraZeneca’s Tagrisso approved in the EU for patients with unresectable NSCLC

AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...

AstraZeneca Plc Imfinzi approved in the US for limited-stage SCLC

AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...

AstraZeneca Plc expands US R&D and manufacturing footprint with $3.5b investment

AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...

AstraZeneca Plc Tezspire meets primary endpoints in WAYPOINT trial

AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients...

AstraZeneca’s Wainzua recommended for approval in the UK

AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...

AstraZeneca Plc completes acquisition of Amolyt Pharma

AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...

Aptamer Group signs agreement with AstraZeneca to explore Optimer delivery vehicles

Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...

AstraZeneca’s Imfinzi plus chemotherapy approved in the US for endometrial cancer

AstraZeneca's Imfinzi gains FDA approval for endometrial cancer treatment. Results show significant benefits for patients with dMMR disease...

AstraZeneca completes acquisition of Fusion Pharmaceuticals

AstraZeneca completes acquisition of Fusion Pharmaceuticals, enhancing its oncology portfolio with next-gen radioconjugates. Learn more here...

AstraZeneca Plc Tagrisso recommended for approval in the EU for NSCLC treatment

AstraZeneca's Tagrisso recommended EU approval for 1st-line treatment of EGFRm NSCLC with positive results from FLAURA2 trial published in NEJM...
Search

Funds

AZN

AstraZeneca’s Tagrisso approved in the EU for patients with unresectable NSCLC

AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...

AstraZeneca Plc Imfinzi approved in the US for limited-stage SCLC

AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...

AstraZeneca Plc expands US R&D and manufacturing footprint with $3.5b investment

AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...

AstraZeneca Plc Tezspire meets primary endpoints in WAYPOINT trial

AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients...

AstraZeneca’s Wainzua recommended for approval in the UK

AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...

AstraZeneca Plc completes acquisition of Amolyt Pharma

AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...

Aptamer Group signs agreement with AstraZeneca to explore Optimer delivery vehicles

Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...

AstraZeneca’s Imfinzi plus chemotherapy approved in the US for endometrial cancer

AstraZeneca's Imfinzi gains FDA approval for endometrial cancer treatment. Results show significant benefits for patients with dMMR disease...

AstraZeneca completes acquisition of Fusion Pharmaceuticals

AstraZeneca completes acquisition of Fusion Pharmaceuticals, enhancing its oncology portfolio with next-gen radioconjugates. Learn more here...

AstraZeneca Plc Tagrisso recommended for approval in the EU for NSCLC treatment

AstraZeneca's Tagrisso recommended EU approval for 1st-line treatment of EGFRm NSCLC with positive results from FLAURA2 trial published in NEJM...
Search

Funds

AZN

FTSE 100

Funds